Skip to main navigation

Our Science
Pipeline & Clinical Trials
- Pipeline
- Previous Clinical Trials
Investors & News
About Us
Contact

Contact IR

Overview
News & Events
Stock Information
Financial Information
Governance
Investor Resources

Investor FAQs
Email Alerts
Contact IR

Investor Contact

Jonathan Carlson
(203) 304-2499
IR@trevitx.com

Name

Email

Subject

Comments

Leave this field blank

Investor Contact

drafts IR@trevitx.com

phone_iphone (203) 304-2499

Subscribe to our Email Alerts

Email Address Required

Privacy Policy
Consumer Health Data Privacy Policy
Terms of Use

Haduvio (nalbuphine ER) is an investigational therapy and not yet approved for use in any indication.

© 2026 Trevi Therapeutics, Inc. All Rights Reserved. Terms of Service.

Search Investors

Search this site